Cyabra, an AI-powered narrative intelligence firm, secured a six-figure contract with a major media company to help detect and differentiate genuine audience reactions from coordinated online manipulation. This technology will enable the media company to identify inauthentic amplification, impersonation threats, and coordinated campaigns targeting its networks and talent. The platform provides early warnings on impersonation and coordinated attacks, helping the media company respond accurately to online controversies. This deal highlights Cyabra's growing influence in narrative intelligence, following its recognition by Gartner as a Market Shaper in 2026.
Cyabra's recent contract with a major media company is notable context for readers. For those tracking the Technology sector, 86 of 150 US stocks rose while 60 fell. Key movers included Applied Digital Corporation at USD 15.56 (+9.81%), Aehr Test Systems at USD 53.59 (+9.01%), and United Microelectronics Corp at USD 14.57 (+8.89%). This snapshot is as of Nov 06, 2026 19:42 WIB.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
